Vaxxas, a clinical-stage biotech company, has appointed three prominent vaccine experts as advisors to guide product development and strategy. These additions aim to support the company’s progress toward later-stage clinical trials and commercialization of its high-density microarray patch (HD-MAP) vaccine technology. The company is focused on advancing its COVID-19, influenza, and RSV vaccine candidates delivered via the HD-MAP.
This move is crucial for Vaxxas as it signals a commitment to accelerating the development and potential market entry of its novel vaccine delivery platform. Securing experienced advisors with expertise in clinical development, regulatory affairs, and manufacturing provides invaluable guidance as the company transitions to larger-scale trials and prepares for eventual commercialization. The focus on key markets like the US and Europe underscores the company’s strategic approach to maximizing impact and accessibility of its technology. This development also represents a significant step towards broader adoption of needle-free vaccine delivery, potentially addressing global vaccination challenges.
Vaxxas’ HD-MAP technology has already undergone five successful Phase I clinical trials, involving more than 500 participants. A US-based Phase I trial for a pre-pandemic influenza vaccine, funded by the Biomedical Advanced Research and Development Authority (BARDA), is also underway. The new advisors join Dr. Charles Knirsch, who joined Vaxxas in July 2024 as a clinical and medical advisor.
The expansion of the advisory team, coupled with ongoing clinical trials and secured funding, positions Vaxxas for significant growth. This strategic move is likely to accelerate the development timeline for HD-MAP delivered vaccines and potentially revolutionize vaccine administration globally in the coming years. The company anticipates commercial availability of its vaccine patches within the next three to five years, signifying a potential paradigm shift in how vaccines are administered worldwide.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
